Protalix Biotherapeutics Inc (PLX)

Currency in USD
1.585
-0.035(-2.16%)
Closed·
1.580-0.020(-1.25%)
·
PLX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.5801.620
52 wk Range
0.8903.100
Key Statistics
Prev. Close
1.62
Open
1.6
Day's Range
1.58-1.62
52 wk Range
0.89-3.1
Volume
340.39K
Average Volume (3m)
796.52K
1-Year Change
74.46%
Book Value / Share
0.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.000
Upside
+783.28%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Protalix Biotherapeutics Inc Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.

Employees
213

Protalix Biotherapeutics Inc Earnings Call Summary for Q2/2025

  • Protalix (PLX) Q2 2025: EPS -$0.04 (136.36% miss), revenue $25.77M (11.56% beat). Stock fell 3.73% premarket.
  • Revenue up 16% YoY, driven by Elfabrio sales. R&D expenses doubled to $6M, impacting profitability.
  • Net income: $164,000, turnaround from $2.2M loss in Q2 2024. Cash and equivalents: $33.4M.
  • PRX-115 Phase II study to begin enrollment in Q4 2025. Targeting $100M+ Elfabrio royalties by 2030.
  • CEO expects up to $500M in milestone payments. No immediate M&A plans announced.
Last Updated: 14/08/2025, 14:26
Read Full Transcript

Compare PLX to Peers and Sector

Metrics to compare
PLX
Peers
Sector
Relationship
P/E Ratio
20.3x−2.4x−0.5x
PEG Ratio
0.15−0.140.00
Price/Book
2.5x2.5x2.6x
Price / LTM Sales
2.1x8.2x3.3x
Upside (Analyst Target)
-171.9%38.7%
Fair Value Upside
Unlock3.0%5.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.000
(+783.28% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-0.04 / 0.11
Revenue / Forecast
25.77M / 23.10M
EPS Revisions
Last 90 days

PLX Income Statement

People Also Watch

18.08
SRPT
-0.99%
46.03
BMNR
-7.85%
2.170
CRDF
-1.81%
28.84
CNC
+0.63%
24.805
SMMT
-8.06%

FAQ

What Stock Exchange Does Protalix Trade On?

Protalix is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Protalix?

The stock symbol for Protalix is "PLX."

What Is the Protalix Market Cap?

As of today, Protalix market cap is 127.17M.

What Is Protalix's Earnings Per Share (TTM)?

The Protalix EPS (TTM) is 0.08.

When Is the Next Protalix Earnings Date?

Protalix will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is PLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Protalix Stock Split?

Protalix has split 2 times.

How Many Employees Does Protalix Have?

Protalix has 213 employees.

What is the current trading status of Protalix (PLX)?

As of 27 Aug 2025, Protalix (PLX) is trading at a price of 1.59, with a previous close of 1.62. The stock has fluctuated within a day range of 1.58 to 1.62, while its 52-week range spans from 0.89 to 3.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.